An interventional study of Cog Fun Ageing intervention and Cog-Fun Aging Crossover in Subjective Cognitive Decline (SCD), Subjective Cognitive Impairment and Subjective Memory Complaints, sponsored by Hebrew University of Jerusalem. Completed at 3 sites in Israel. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.
Sponsored by Hebrew University of Jerusalem · Not applicable, Interventional, and Supportive care
Among 53 studies in Cognitive Dysfunction with a site in Israel — 5 open to participants now, 7 under way, none of them phase 3. Cognitive Dysfunction · Israel.
Among the 53 studies in Cognitive Dysfunction with a site in Israel, this one is the 26th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2024, is one of 22 with no phase, and was the 48th registered.
3,872 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.
Browse Cognitive Dysfunction studies →5 of the 53 studies in Cognitive Dysfunction with a site in Israel are open now. Recruiting first, the newest first:
Hadassah Medical Organization · Sites in Israel
Rutgers, The State University of New Jersey · Sites in Israel
Assaf-Harofeh Medical Center · Sites in Israel
Rambam Health Care Campus · Sites in Israel
Hadassah Medical Organization · Sites in Israel
A study can be open while its sites in Israel have not opened yet or have stopped. Only those recruiting at a site in Israel →
Of the 750 Cognitive Dysfunction studies recruiting now, 362 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 259 take healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
53 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 3 · Phase 4 1
First in 2000; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 27 is below the median of 64 across 2,794 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 50 across the 33 interventional studies, 99 across the 20 observational. Of the 23 that completed or were terminated, 5 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 53 have an industry lead sponsor. The 10 most frequent:
Hebrew University of Jerusalem is the lead sponsor of 31 studies on the registry; 4 are open to participants now.
Hebrew University of Jerusalem has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
3 of the studies in Cognitive Dysfunction with a site in Israel that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07287852Hadassah Medical OrganizationA Pilot Study to Examine the Effect of Egb761 on Plasma Biomarker Levels and on Cognitive Function in Patients With MCI | 2026-12 |
| NCT07596186Soroka University Medical CenterPredict Early Cognitive Changes in a Healthy Elderly Population by Passively Recording Sensor Data From Mobile Devices | 2027-01-01 |
| NCT07591857Hadassah Medical OrganizationThe Computerized Retraining and Functional Treatment - Group Intervention | 2027-10 |
Among the 53 studies in Cognitive Dysfunction with a site in Israel, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to learn if the Cog-Fun Aging program helps older adults with Subjective Cognitive Decline (SCD) manage memory challenges and improve their daily lives. The main questions it aims to answer are:
Researchers will compare participants who complete the Cog-Fun Aging program with those who do not to determine the program's effectiveness.
Participants will:
Take part in a 10-week program with weekly sessions. Learn about SCD and how it affects daily life. Practice and monitor strategies to manage memory difficulties.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the control arm will not receive the Cog-Fun Aging intervention during the initial phase (10 weeks). Instead, they will undergo baseline assessments (T0) alongside the intervention group. After the first group completes the 10-week program, the control arm participants will be assessed again (T1). They will then begin the 10-week Cog-Fun Aging intervention and complete a final assessment (T2) after the intervention to evaluate its effects.
Other: Cog-Fun Aging Crossover
Other: Cog Fun Ageing intervention
Cog Fun Aging is a group-based intervention aimed at promoting positive occupational experiences despite cognitive challenges in day to day life. The intervention includes 10 weekly 120-minute group sessions led by experienced occupational therapists. Sessions incorporate learning about the bio-psycho-social factors of SCD and strategies to manage and cope with occupational challenges resulting from SCD.
In the initial phase of the study (between T0 and T1) this group will receive "usual care". Participants are users of regional services where activities for healthy older adults are available. This group will continue going to activities as normal during the initial phase and then participate in the Cog-Fun Aging intervention.
Memory Impact Questionnaire (MIQ)
The questionnaire was developed for use in both clinical and research settings to better understand the impact of memory changes on the day-to-day functioning of older adults and to monitor outcomes of support programs for this population. In this study the new short form (27 items), not yet published, was used with permission by the authors of the MIQ. The questionnaire includes three subscales: Lifestyle Restrictions (social relationships, work, volunteer and leisure activities), Positive Coping (participation in cognitively engaging tasks and other positive responses to memory changes), and Negative Emotions (negative self-perceptions and perceived negative judgments from others). The total score reflects the overall burden of memory changes, with higher scores indicating with higher scores indicating a greater negative impact. The MIQ has psychometric support, including test-retest reliability (rs = .65-.91) and internal consistency (αs = .87-.93)
Time frame: After enrollment (before intervention) and 10 weeks later (after intervention)
Multifactorial Memory Questionnaire-Short Version (MMQ-9)
The short version is a 9 item questionnaire that assesses metamemory. It consists of three scales measuring satisfaction with one's memory (MMQ Satisfaction), self-perception of one's everyday memory abilities (MMQ-Ability), and use of practical memory strategies in day-to-day life (MMQ Strategy). Items are rated on a 5-point Likert scale. The MMQ-9 demonstrates strong psychometric properties, with Cronbach's alpha scores of 0.92 for Satisfaction, 0.86 for Ability, and 0.79 for Strategy, indicating high internal consistency, and intraclass correlation coefficients of 0.89, 0.84, and 0.78, respectively, showing good test-retest reliability. Convergent validity is supported by correlations with related measures (e.g., 0.74 for Satisfaction and 0.70 for Strategy), while discriminant validity is confirmed by negligible correlations with unrelated constructs (e.g., 0.08 for Satisfaction).
Time frame: After enrollment (before intervention) and 10 weeks later (after intervention)
Self-Regulation Skills Interview (SRSI) - adpated for study
Evaluates an individual's ability to articulate self-regulation and metacognitive skills in relation to daily life challenges. Includes 6 items that address key domains: emergent awareness, anticipatory awareness, readiness to change, strategy knowledge, strategy use, and strategy effectiveness. In this study, 5 of the 6 items will be utilized, excluding the readiness-to-change domain. Responses are scored on a 10-point scale, and scores are summarized and averaged into two main indices: awareness of difficulties and strategic behavior. Lower scores on these indices indicate stronger abilities in self-monitoring, recognizing, and anticipating difficulties, as well as identifying and effectively applying strategies to manage challenges. The tool demonstrates excellent psychometric properties, with interrater reliability ranging from 0.81 to 0.92 and test-retest reliability between 0.69 and 0.91.
Time frame: After enrollment (before intervention) and 10 weeks later (after intervention)
SCD Awareness of Cognitive Difficulties in Daily Life Interview (SCD Interview)
A made-for-study interview to assess participants' ability to describe detailed events in which they encountered cognitive challenges in everyday life and gauge their capacity to identify and articulate the thoughts and emotions that influenced their experiences, the contextual factors that supported or hindered cognitive functioning, the strategies they employed, and how they monitored those strategies' effectiveness in real-time during negative SCD-related daily experiences. Together, the SRSI and the SCD Interview) will provide a comprehensive understanding of participants' awareness of difficulties and strategy use, supporting the evaluation of intervention outcomes.
Time frame: After enrollment (before intervention) and 10 weeks later (after intervention)
Patient Health Questionnaire for Depression and Anxiety (PHQ-4)
A 4 item questionnaire that assesses emotional health. The tool combines the PHQ-2 for depression and the GAD-2 for anxiety, featuring a 4-point scale for responses, with total scores ranging from 0 to 12. Higher scores indicate more severe symptoms. The PHQ-4 has strong psychometric support, including internal reliability, construct validity, and factorial validity and criterion validity.
Time frame: After enrollment (before intervention) and 10 weeks later (after intervention)
Plan to share: No — The study is still in its early stage a research program which aims to enhance the occupational experiences of individuals with Subjective Cognitive Decline (SCD) and identify or develop measures that effectively capture changes in occupational experiences following an intervention. At this stage, the investigators are still assessing whether the data collected by the current measures will adequately reflect the experiences the study seeks to understand and address.
Ran from Nov 2024 to primary completion in Jul 2025, 8 months.
Of 1,442 non-industry interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 51. This study's 8 months is below that.
Counting every sponsor, half of 1,511 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hebrew University of Jerusalem